Hong Kong · Delayed Price · Currency is HKD 3SBio Company Description
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China.
The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy.
It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis.
In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up.
Further, the company provides trading, project management and consultation, technology, and agricultural services.
It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute.
The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
| Country | Hong Kong |
| Founded | 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6,109 |
| CEO | Jing Lou |
Contact Details
Address: No. 3 A1, Road 10 Shenyang China | |
| Phone | 86 24 2538 6000 |
Stock Details
| Ticker Symbol | 1530 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG8875G1029 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jing Lou M.D., Ph.D. | Co-Founder, Executive Chairman, Chief Executive Officer and President |
| Dr. Dongmei Su | Senior Vice President and Executive Director |
| Xiang He | Chief Financial Officer |
| Siu Kuen Lai FCIS, FCS | Company Secretary |
| Yong Xu | General Manager of Shenzhen Sciprogen Bio-pharmaceutical Technology Co., Ltd. |
| Yanli Liu | General Manager of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
| Zheng Jin | General Manager of Shenyang Sunshine Pharmaceutical Co., Ltd. |